CJC-1295 DAC 5 mg

Dragon Pharma CJC-1295 DAC

CJC-1295 DAC 5 mg delivers a potent, long-acting analog of Growth Hormone-Releasing Hormone (GHRH), engineered with a revolutionary Drug Affinity Complex (DAC) that fundamentally alters its pharmacokinetic profile. The DAC moiety enables covalent binding to serum albumin upon administration, creating a circulating reservoir that slowly releases the active peptide over an extended period. This results in an exceptionally long half-life of approximately 7-10 days, compared to minutes for the native GHRH hormone or the "No DAC" version. The sustained presence of CJC-1295 DAC provides continuous stimulation of the pituitary gland to release growth hormone (GH), leading to stable, elevated IGF-1 levels for prolonged periods from a single administration.

For bodybuilders, athletes, and anti-aging researchers in the USA, Dragon Pharma CJC-1295 DAC 5 mg offers a unique research paradigm focused on sustained anabolic and metabolic stimulation. Unlike pulsatile GH secretagogues, CJC-1295 DAC creates a more constant "background" elevation of GH and IGF-1, which may be particularly useful in studies examining long-term tissue repair, chronic injury healing, and sustained improvements in body composition. This makes it a compelling research tool for protocols that benefit from continuous exposure rather than intermittent pulses. Manufactured by Dragon Pharma in certified European laboratories, each 5 mg vial of lyophilized powder represents the pinnacle of peptide engineering, providing researchers with a consistent, high-purity compound for investigating prolonged endocrine modulation.

Key Benefits:

• Extended Duration of Action: DAC modification creates a half-life of 7-10 days, enabling once- or twice-weekly dosing protocols for sustained research effects.
• Sustained GH/IGF-1 Elevation: Provides continuous stimulation of the somatotropic axis, maintaining elevated IGF-1 levels for prolonged periods from minimal administrations.
• Enhanced Research Convenience: Infrequent dosing schedule (1-2 times weekly) simplifies study protocols and improves compliance in long-term research models.
• Potent Anabolic & Metabolic Effects: Research focuses on sustained benefits for muscle growth, fat metabolism, connective tissue repair, and anti-aging parameters.
• Albumin-Binding Technology: Innovative DAC moiety binds to circulating albumin, creating a stable depot that slowly releases the active peptide for prolonged activity.

Each 2 mL vial contains 5 mg of high-purity CJC-1295 with Drug Affinity Complex as a sterile lyophilized powder, synthesized using advanced peptide chemistry under Dragon Pharma's rigorous quality control standards.

Product Specifications

Usage Guidelines

Research Application Only: This information is derived from scientific literature for educational purposes. Dragon Pharma CJC-1295 DAC 5 mg is a research chemical for laboratory investigation only, not for human consumption.

In experimental settings, CJC-1295 DAC is reconstituted with bacteriostatic water. Its extraordinary half-life allows for very infrequent dosing—once or twice weekly is standard in research protocols. Studies often begin with a single weekly dose to establish baseline effects. Due to its continuous action, research monitoring should include regular assessment of IGF-1 levels, glucose metabolism, and potential fluid retention. Subcutaneous administration is most common in preclinical models. The sustained nature of its effects means research outcomes are typically evaluated over weeks rather than days.

• Standard Long-Term Research Cycle (8-12 weeks): Once-weekly administration protocol to study sustained effects on body composition, recovery markers, and metabolic parameters.
• Intensive Anabolic Study Protocol (12+ weeks): Twice-weekly dosing may be used in research models focusing on maximal muscle protein synthesis and connective tissue remodeling.

Post Cycle Therapy (PCT):

As a GHRH analog, CJC-1295 DAC does not suppress the hypothalamic-pituitary-gonadal (HPG) axis, so traditional PCT with SERMs like Nolvadex is not indicated. However, due to its long-acting nature and potential for pituitary desensitization with prolonged use, research protocols typically include a washout period of 4-6 weeks after a cycle. Some studies incorporate a switch to a pulsatile secretagogue like Ipamorelin or the CJC No DAC/Ipamorelin blend during the off-period to maintain some GH stimulation while allowing receptor recovery.

Synergistic Research & Metabolic Support:

CJC-1295 DAC is often studied in combination with other compounds. For enhanced anabolic research, it can be paired with SARMs like YK-11 (a myostatin inhibitor) or MK-2866 (Ostarine). For fat loss synergy, researchers may combine it with GW501516 (Cardarine). Due to potential effects on blood sugar, monitoring glucose and considering support with compounds like Sermorelin (which may have different metabolic effects) could be part of comprehensive study designs.

Storage Instructions

Proper storage is essential to maintain the stability of this advanced peptide conjugate.

• Unreconstituted Powder: Store the sealed vial in a freezer at -20°C (-4°F) or colder. In this lyophilized state, CJC-1295 DAC remains stable for up to 24 months. Protect from light and avoid temperature fluctuations that could degrade the DAC complex.
• After Reconstitution: Once reconstituted with bacteriostatic water, the solution must be refrigerated immediately at 2°C to 8°C (36°F to 46°F). The reconstituted solution is typically stable for research use for 4-6 weeks when refrigerated, though using within 30 days is recommended for optimal integrity. Never freeze the reconstituted solution.
• Important Note: The DAC modification may make the peptide more stable in solution than some others, but maintaining cold chain storage for both powder and solution is critical for research reliability.